At 26 weeks of treatment, patients with type 2 diabetes randomized to insulin glargine had reductions in mean TG (insulin naïve: −11 mg/dL; prior insulin use: <4 mg/dL); patients with type 1 diabetes had reductions of <2.0 mg/dL. This evidence concerns the gene INS and type 1 diabetes mellitus.